Introduction
Ipamorelin is a selective growth hormone secretagogue — a synthetic pentapeptide that stimulates the pituitary gland to release growth hormone (GH) in a pulsatile, physiologically natural manner. Unlike older GH secretagogues, Ipamorelin is highly selective: it stimulates GH release without significantly elevating cortisol, prolactin, or ACTH, making it one of the cleanest and most well-tolerated GH-axis peptides available. It is widely used in integrative medicine for body composition optimization, anti-aging, recovery, and sleep quality.
What Is Ipamorelin?
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide ghrelin mimetic — it binds the growth hormone secretagogue receptor (GHSR-1a), the same receptor activated by ghrelin (the "hunger hormone"). However, unlike ghrelin, Ipamorelin does not significantly stimulate appetite or cortisol release at therapeutic doses, and unlike GHRP-6 and GHRP-2 (older secretagogues), it has minimal off-target hormonal effects.
Ipamorelin works synergistically with GHRH analogs (such as CJC-1295 or Sermorelin) — the two classes act on complementary receptors to amplify GH release far beyond what either achieves alone.
Root Causes Ipamorelin Addresses
- Age-related GH decline (somatopause) — GH pulsatility decreases ~14% per decade after age 30
- Poor body composition — excess adiposity, reduced lean muscle mass
- Impaired recovery and tissue repair — GH is essential for IGF-1 production and anabolic repair
- Sleep disruption — GH is primarily secreted during slow-wave sleep; restoring GH pulsatility improves sleep architecture
- Metabolic dysfunction — GH deficiency is associated with insulin resistance, dyslipidemia, and central adiposity
- Reduced bone density — GH/IGF-1 axis is critical for bone remodeling
Mechanisms of Action
1. GHSR-1a Agonism
Ipamorelin binds GHSR-1a on somatotroph cells in the anterior pituitary, triggering intracellular cAMP production and calcium influx, which drives GH vesicle exocytosis. The result is a sharp, pulsatile GH release that mimics the natural GH pulse pattern — critical for maintaining receptor sensitivity and avoiding the desensitization seen with continuous GH administration.
2. Somatostatin Suppression
Ipamorelin partially suppresses somatostatin (the GH-inhibiting hormone) at the hypothalamic level, reducing the brake on GH release and amplifying the net GH pulse. This mechanism complements GHRH analogs, which stimulate GH release from the opposite direction.
3. IGF-1 Upregulation
GH released in response to Ipamorelin travels to the liver and peripheral tissues, stimulating IGF-1 (Insulin-like Growth Factor-1) production. IGF-1 mediates most of GH's anabolic effects: protein synthesis, muscle hypertrophy, fat oxidation, bone remodeling, and tissue repair.
4. Lipolysis and Fat Oxidation
GH directly stimulates lipolysis in adipose tissue via hormone-sensitive lipase activation, releasing free fatty acids for oxidation. This effect is particularly pronounced in visceral adipose tissue, making GH secretagogues valuable for central adiposity reduction.
5. Sleep Architecture Improvement
GH is predominantly secreted during slow-wave (deep) sleep. Ipamorelin, when dosed before sleep, amplifies the nocturnal GH pulse, which in turn deepens slow-wave sleep — creating a positive feedback loop between GH secretion and sleep quality.
Clinical Evidence
- GH release: Ipamorelin produces dose-dependent GH release with high selectivity; no significant cortisol or prolactin elevation at therapeutic doses
- Body composition: GH secretagogue studies consistently show reduced fat mass and increased lean mass over 3–6 months
- Bone density: IGF-1 elevation associated with improved bone mineral density in GH-deficient populations
- Safety: Ipamorelin has an excellent safety profile in clinical studies with no serious adverse events reported
Integrative Protocols
Standard Dosing
- Dose: 200–300 mcg per injection
- Frequency: Once daily (before sleep) or twice daily (morning fasted + before sleep)
- Route: Subcutaneous injection
- Cycle: 3–6 months on, 1–2 months off
Timing Principles
- Dose on an empty stomach — food (especially carbohydrates) blunts GH release via insulin elevation
- Pre-sleep dosing aligns with the natural nocturnal GH pulse for maximum effect
- Morning fasted dosing targets the secondary GH pulse and supports daytime fat oxidation
Common Stacks
- Ipamorelin + CJC-1295 — the gold standard GH stack; GHSR-1a agonism + GHRH receptor agonism for synergistic GH amplification
- Ipamorelin + Sermorelin — similar synergy with shorter-acting GHRH analog; preferred for more physiological pulsatility
- Ipamorelin + BPC-157 + TB-500 — comprehensive recovery and repair stack
Safety Profile
Ipamorelin is one of the safest GH secretagogues available. Common minor effects include:
- Mild water retention (transient, resolves with dose adjustment)
- Tingling or numbness in extremities (carpal tunnel-like; dose-dependent)
- Mild headache (uncommon)
- Increased hunger (less than GHRP-6; generally mild)
Contraindications: Active malignancy (GH/IGF-1 elevation may promote tumor growth); diabetic retinopathy; pregnancy.
Monitoring
Baseline and follow-up labs recommended:
- IGF-1 (primary marker of GH axis activity; target upper quartile of age-appropriate range)
- Fasting glucose and insulin (GH can induce transient insulin resistance)
- Thyroid panel (GH affects T4→T3 conversion)
Conclusion
Ipamorelin is the benchmark GH secretagogue for integrative medicine — selective, well-tolerated, and highly effective when dosed correctly. Its ability to restore physiological GH pulsatility without the side effect burden of older secretagogues or exogenous GH makes it the preferred starting point for GH axis optimization. When combined with a GHRH analog like CJC-1295, it delivers the most potent and physiologically appropriate GH stimulation available without a prescription.